Stockreport

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights [Yahoo! Finance]

Structure Therapeutics Inc.  (GPCR) 
PDF Phase 2b study in obesity expected to begin as planned in the fourth quarter 2024 Year-end cash balance of $467.3 million expected to fund operations and key clinic [Read more]